Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IcoSema vs insulin glargine/aspart in type 2 diabetes
NCT05013229Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2021
- Primary completion
- Nov 2023
- Modality
- Peptides
- Countries
- 14
01
Overview
A Phase 3 trial of icosema in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Nov 2021; status: completed.
02
Drugs
icosema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05013229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013229.